MedTrace Logo

Evaluation of the New Variant 501Y.V2 of COVID-19

NCT04906850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2021-06-02

No results posted yet for this study

Summary

In January 2021, the incidence of COVID-19-and its mortality started rising for the third time in France. This rise may associate with three emerging variants, namely, V1, V2, and V3, which are the 20I/501Y.V1 ("English"), 20H/501Y.V2 ("South African"), and 20J/501Y.V3 ("Brazilian") variants, respectively. V1 was recently suggested to increase mortality in people in the United Kingdom who tested positive for COVID-19 on community screening. Very little is known about V2 infection, including its outcomes relative to other strains. In early 2021, V2 spread to the Grand-Est region (northeastern France). Here, the investigators aimed to report mortality data of patients admitted in ICU between February and April 2021 in 3 hospitals in Grand-Est: Metz, Thionville and Nancy.

Conditions

  • Covid19

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    collaborator OTHER

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-04-15
Completion
2021-05-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906850 on ClinicalTrials.gov